Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma
This article was originally published in The Pink Sheet Daily
Swiss Nycomed has acquired a majority stake in Guangdong Techpool Bio-Pharma for €210 million to expand its Chinese operations.
You may also be interested in...
MUMBAI - Having established itself firmly among the top 10 pharma companies in Russia, Zurich-headquartered Nycomed now plans to dig deeper into the fast-growing Chinese market through the acquisition of a sales and distribution team
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.